Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07397572

Iron Supplementation and Anemia After Sleeve Gastrectomy

The goal of this observational study is to learn if taking extra iron pills after weight loss surgery helps prevent low iron and anemia compared to just taking a standard multivitamin. The main question it aims to answer is:

Does a specific iron supplementation plan lower the number of patients who develop iron deficiency anemia in the 6 months after sleeve gastrectomy surgery?

Researchers will compare two groups of patients from different hospital units to see if the extra iron works:

Patients from one unit who take a prophylactic iron supplement (Ferrodep, 60 mg per day) in addition to their standard multivitamin.

Patients from another unit who take only a standard multivitamin (Centrum Silver).

Participants in this study will:

* Have their blood tested for iron and anemia levels before surgery, and again at 3 and 6 months after surgery, as part of their regular post-operative care. * Be asked about their health and quality of life during follow-up clinic visits. * Have their medical information from their hospital records reviewed by the study team to track their progress.

Recruiting

Interested in participating?

Request Info

Key information

About this study

Background and Rationale Iron deficiency anemia (IDA) is a prevalent and clinically significant long-term complication following Laparoscopic Sleeve Gastrectomy (LSG), the most commonly performed bariatric procedure worldwide. Despite universal multivitamin supplementation, the incidence of IDA rises steadily post-operatively, impacting patient quality of life, cognitive function, and healthcare utilization. A critical evidence gap exists regarding the efficacy of routine prophylactic oral iron supplementation compared to a strategy of standard multivitamin use with iron monitoring. Current guidelines lack consensus due to insufficient comparative long-term data. This study aims to provide high-level evidence to inform postoperative protocols by directly comparing these two distinct management strategies.

Study Design and Setting This is a prospective, observational, comparative cohort study conducted within the bariatric surgery units of Kasr Al-Ainy Hospital, Cairo University. The study leverages existing, routine clinical practices at two participating units, allowing for a real-world comparison of outcomes. Participants will be managed according to the standard post-operative supplementation protocol of their treating surgical unit; the research protocol does not assign interventions.

Study Cohorts

Eligible participants will be enrolled into one of two cohorts based on the standard care protocol of their surgical unit:

Prophylactic Iron Cohort: Patients whose standard care includes a daily prophylactic dose of 60 mg elemental iron (administered as Ferrodep®, 30 mg capsule every 12 hours) in addition to a daily standard multivitamin.

Standard Multivitamin Cohort: Patients whose standard care includes a daily standard multivitamin only (e.g., Centrum Silver®), which contains approximately 10 mg of iron, with no additional prophylactic iron.

Study Procedures and Assessments Consecutively enrolled patients scheduled for primary LSG will be assessed pre-operatively (baseline) and at 3 and 6 months post-operatively. Data collection will include standardized laboratory panels (hemoglobin, ferritin, iron studies, complete blood count indices), documentation of supplementation adherence, and patient-reported outcome measures. All primary and secondary outcome measures are pre-specified and listed in the designated module.

Statistical Considerations The primary outcome is the cumulative incidence of IDA at 6 months post-surgery, with IDA defined per protocol-specific laboratory criteria. Secondary outcomes include longitudinal changes in hematological parameters, adherence rates, and patient-reported fatigue. A sample size of 66 participants (33 per cohort) was calculated to provide 85% power to detect a significant difference in the primary outcome. Data will be analyzed using SPSS software with appropriate statistical tests for between-group comparisons, as detailed in the statistical analysis plan.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults aged 18 to 65 years scheduled to undergo primary laparoscopic sleeve gastrectomy (LSG).
  • Capable of understanding and providing written informed consent for participation.
  • Able and willing to commit to the 6-month post-operative follow-up schedule at the bariatric clinic.

Exclusion criteria

  • Prior history of major gastrointestinal surgery (e.g., bowel resection, gastrectomy) that could independently affect iron absorption.
  • Pre-existing malabsorptive conditions (e.g., inflammatory bowel disease, celiac disease).
  • Diagnosis of other known forms of anemia (e.g., thalassemia, vitamin B12/folate deficiency, anemia of chronic disease) that would confound the diagnosis of iron deficiency anemia (IDA).
  • Any condition that, in the investigator's judgment, would interfere with full participation in the study or pose a significant risk.

Treatment and study plan

Elemental Iron

Drug

Prophylactic oral iron supplement (Ferrodep®), prescribed as part of the standard post-operative care protocol at the participating unit. Each capsule contains 30 mg of elemental iron. The regimen is one capsule every 12 hours, for a total daily dose of 60 mg elemental iron, taken in addition to a daily multivitamin.

Multivitamin with Minerals

Dietary Supplement

A standard daily multivitamin with minerals (Centrum Silver®), prescribed as part of the routine post-operative care. This formulation contains approximately 10 mg of elemental iron. For participants in this unit's protocol, no additional prophylactic iron is routinely prescribed.

Primary outcomes

  1. Incidence of Iron Deficiency Anemia (IDA) at 6 Months

    Time frame: 6 Months Post-Surgery

    Proportion of participants diagnosed with IDA. Diagnosis requires: 1) Anemia (Hemoglobin <13 g/dL in males or <12 g/dL in females), AND 2) Iron Deficiency, defined by at least one of: serum ferritin <30 ng/mL, TIBC >450 µg/dL, or serum iron <75 µg/dL (male)/<60 µg/dL (female).

Secondary outcomes

  1. Change in Hemoglobin Concentration

    Time frame: Baseline, 3 Months, 6 Months

    Mean change in hemoglobin concentration (g/dL) from baseline to follow-up.

  2. Change in Serum Ferritin Level

    Time frame: Baseline, 3 Months, 6 Months

    Mean change in serum ferritin concentration (ng/mL) from baseline to follow-up.

  3. Change in Transferrin Saturation (TSAT)

    Time frame: Baseline, 3 Months, 6 Months

    Mean change in Transferrin Saturation percentage, calculated from serum iron and TIBC.

  4. Incidence of Isolated Iron Deficiency without anemia

    Time frame: 3 Months, 6 Months

    Proportion of participants with serum ferritin <30 ng/mL and normal hemoglobin (≥12 g/dL female, ≥13 g/dL male).

  5. Rate of Oral Iron Intolerance

    Time frame: 6 Months Post-Surgery

    Proportion experiencing gastrointestinal effects leading to dose reduction, interruption, or discontinuation of iron.

  6. Adherence to Oral Supplementation

    Time frame: 3 Months, 6 Months

    Adherence expressed as the percentage of prescribed doses taken, calculated from pill count at follow-up clinic visits.

  7. Fatigue Severity Score]

    Time frame: Baseline, 3 Months, 6 Months

    Mean score on the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) scale.The FACIT-Fatigue scale consists of 13 items, with total scores ranging from 0 to 52, where higher scores indicate less fatigue and better quality of life.

  8. Need for Therapeutic Iron Supplementation

    Time frame: 6 Months Post-Surgery

    Proportion of participants who require initiation of new therapeutic iron during follow-up per clinician judgment.

Study contacts

Contact information is provided by the study sponsor or research team.

Ahmed Eid Aziz, Lecturer

CONTACT

[email protected]

+201127060844

Sponsors and collaborators

Lead sponsor

Cairo University

Other

Registry information

Official study title

Prophylactic Oral Iron Supplementation for the Prevention of Iron Deficiency Anemia After Sleeve Gastrectomy: A Prospective Comparative Cohort Study

Important dates

Study start
2026
Primary completion
2026
Study completion
2027
First posted
Feb 9, 2026
Registry last updated
Feb 11, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.